Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP); Initial Review, 31909 [2015-13622]

Download as PDF Federal Register / Vol. 80, No. 107 / Thursday, June 4, 2015 / Notices Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. DEPARTMENT OF HEALTH AND HUMAN SERVICES Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2015–13620 Filed 6–3–15; 8:45 am] Food and Drug Administration [Docket No. FDA–2015–N–0002] Withdrawal of Approval of New Animal Drug Application; Chlortetracycline AGENCY: BILLING CODE 4163–18–P Food and Drug Administration, HHS. Notice of withdrawal of approval. ACTION: DEPARTMENT OF HEALTH AND HUMAN SERVICES The Food and Drug Administration (FDA) is withdrawing approval of a new animal drug application (NADA). This action is being taken at the sponsors’ request because this product is no longer manufactured or marketed. DATES: Withdrawal of approval is effective June 15, 2015. FOR FURTHER INFORMATION CONTACT: Sujaya Dessai, Center for Veterinary Medicine (HFV–212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–276–9075, sujaya.dessai@fda.hhs.gov. SUPPLEMENTARY INFORMATION: The Hartz Mountain Corp., 400 Plaza Dr., Secaucus, NJ 07094 has requested that FDA withdraw approval of NADA 065– 222 for KEET LIFE (chlortetracycline) Bird Seed because this product is no longer manufactured or marketed. Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with 21 CFR 514.116 Notice of withdrawal of approval of application, notice is given that approval of NADA 065–222, and all supplements and amendments thereto, is hereby withdrawn, effective June 15, 2015. The animal drug regulations are not being amended to reflect the voluntary withdrawal of approval of this application because it is not codified. SUMMARY: Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP); Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to Funding Opportunity Announcement, RFA–TS–15–001, Analyze and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS). wreier-aviles on DSK5TPTVN1PROD with NOTICES Times and Dates: 9:00 a.m.–5:00 p.m., EDT, June 30, 2015 (CLOSED). Place: The Georgian Terrace, 659 Peachtree Street NE., Atlanta, Georgia 30308. This meeting will also be held by teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Analyze and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)’’, TS15–001. Contact Person for More Information: Jane Suen, Dr.P.H., M.S., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F63, Atlanta, Georgia 30341–3724, Telephone (770) 488–4281. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2015–13622 Filed 6–3–15; 8:45 am] BILLING CODE 4163–18–P VerDate Sep<11>2014 15:33 Jun 03, 2015 Jkt 235001 31909 The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Heart, Lung, and Blood Initial Review Group, NHLBI Mentored Clinical and Basic Science Review Committee. Date: June 25–26, 2015. Time: 10:30 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: Crystal City Marriott, 1999 Jefferson Davis Highway, Arlington, VA 22202. Contact Person: Keith A. Mintzer, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7186, Bethesda, MD 20892–7924, 301–594– 7947, mintzerk@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: May 29, 2015. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–13604 Filed 6–3–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2011–1156] Dated: June 1, 2015. Bernadette Dunham, Director, Center for Veterinary Medicine. Change-1 to Navigation and Inspection Circular 01–13, Inspection and Certification of Vessels Under the Maritime Security Program [FR Doc. 2015–13633 Filed 6–3–15; 8:45 am] AGENCY: BILLING CODE 4164–01–P ACTION: Coast Guard, DHS. Notice of availability. The Coast Guard announces the availability of Change-1 to Navigation and Vessel Inspection Circular (NVIC) 01–13, Inspection and Certification of Vessels Under the Maritime Security Program (MSP). The MSP serves as a means for establishing a fleet of commercially viable and militarily useful vessels to meet national defense as well as other security requirements. NVIC 01–13 provides guidance to assist vessel owners/ SUMMARY: DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. PO 00000 Frm 00024 Fmt 4703 Sfmt 4703 E:\FR\FM\04JNN1.SGM 04JNN1

Agencies

[Federal Register Volume 80, Number 107 (Thursday, June 4, 2015)]
[Notices]
[Page 31909]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-13622]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP); Initial Review

    In accordance with Section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces a meeting for the initial review of 
applications in response to Funding Opportunity Announcement, RFA-TS-
15-001, Analyze and Evaluate Potential Risk Factors for Amyotrophic 
Lateral Sclerosis (ALS).

    Times and Dates: 9:00 a.m.-5:00 p.m., EDT, June 30, 2015 
(CLOSED).
    Place: The Georgian Terrace, 659 Peachtree Street NE., Atlanta, 
Georgia 30308. This meeting will also be held by teleconference.
    Status: The meeting will be closed to the public in accordance 
with provisions set forth in Section 552b(c)(4) and (6), Title 5 
U.S.C., and the Determination of the Director, Management Analysis 
and Services Office, CDC, pursuant to Public Law 92-463.
    Matters for Discussion: The meeting will include the initial 
review, discussion, and evaluation of applications received in 
response to ``Analyze and Evaluate Potential Risk Factors for 
Amyotrophic Lateral Sclerosis (ALS)'', TS15-001.
    Contact Person for More Information: Jane Suen, Dr.P.H., M.S., 
Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop 
F63, Atlanta, Georgia 30341-3724, Telephone (770) 488-4281.

    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2015-13622 Filed 6-3-15; 8:45 am]
 BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.